Abide Therapeutics Inc. logo

Abide Therapeutics Inc.

With an initial focus on CNS disorders, we develop innovative medicines that target serine hydrolases. Abide Therapeutics is focused on developing innovative small molecule therapeutics, which targets serine hydrolases, an enzyme that plays an important regulatory roles in human physiology and disease.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://abidetx.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
10835 Road to the Cure, Suite 250, CA 92121
San Diego
United States
Email
Contact Number
+1 858-427-2590

In Nov 2014, Abide entered into a collaborative three years agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases and role of monoacylglycerol lipase (MGLL) inhibitors in altering endocannabinoid tone in the human brain.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/abide-therapeutics” connections=”true” suffix=””]

Abide has created a proprietary platform, based on technology developed at The Scripps Research Institute by Professors Ben Cravatt and Dale Boger, that specifically targets serine hydrolases with selective small molecules.

In Feb 2014, Abide entered into a collaboration with Celgene to discover & develop new drugs in inflammation & immunology. Under the terms Celgene paid an upfront payment of $50 Mn with an unspecified milestones and small equity investment in Abide.